Latest news and research on all cancers and treatments, updated several times a week
Cancer cells need cholesterol to break off from tumours
Statins are effective against cells similar to those behind cancer
Researchers suggest that statins should be given alongside treatments such as surgery, chemotherapy and radiotherapy
Dr. Darren Sigal, a cancer physician and researcher at Scripps Clinic in La Jolla, spends much of his time helping patients battle pancreatic cancer, ...
New research from the University of Michigan Comprehensive Cancer Center helps explain why pancreatic cancer is so lethal, with fewer than a third ...
What makes pancreatic cancer so aggressive? New study sheds light - University of Michigan Comprehensive Cancer Center
Brower's article notes that even more effort is needed to develop new pancreatic cancer treatments because by 2030, the disease, which is currently ...
Target these cancer stem cells specifically, the thinking goes, and the ... combined tarextumab with two conventional drugs for pancreatic cancer—a ...
“Dr. Seyfried says: "cancer is primarily a metabolic disease involving disturbances in energy production through respiration and fermentation."(1) Electron microscope studies have shown abnormalities in the mitochondria of cancer cells.(2) The cancer cell's mitochondria have undergone "metabolic reprogramming," thereby providing a key which can be exploited to devise a more selective cancer treatment”
“Laboratory research suggests that vitamin D boosts immune system ... role in the immune system account for the lower rates of colorectal cancer in ...
UroSens Ian Campbell CEO A company aiming to replace the uncomfortable and invasive biopsies used to detect prostate and bladder cancer with a ...
However, approximately 90% of cancer-specific targets are actually ... It is an exciting time in cancer immunotherapy, and the potential of CAR cell ...
Dr. Yannelli has published nearly 100 articles and book chapters on the immunotherapy of human cancer and continues research to improve ...
“This less-intense, every other week treatment approach seems to be effective in treating our patients with metastatic pancreatic cancer while ...
Study Rundown: Pancreatic adenocarcinoma (PAC) is the fourth leading cause ofcancer-related deaths in the United States. In patients with ...
Cold Spring Harbor and Bethpage, N.Y. – Pancreatic cancer is one of the most deadly forms of cancer, with only 6 percent of patients surviving five ...
"The positive data from the Phase 1b study of tarextumab in first line pancreatic cancer patients provide us with clear support for the advancement of ...
In particular, we are most excited about the long-term survival shown in patients with liver and pancreatic cancers. The long-term survival is consistent ...
ADT Risks and Side Effects in Advanced Prostate Cancer: Cardiovascular and Acute Renal Injury
We review recent evidence suggesting an increased risk of pneumonia, cardiovascular disease, and acute kidney injury in men treated with ADT and consider whether the incidence of such events differs with the treatment modality. We discuss possible mechanisms by which such events might be mediated, including the roles of testosterone and the GnRH receptor, and consider current guidelines in light of these data.
We review recent evidence suggesting an increased risk of pneumonia, cardiovascular disease, and acute kidney injury in men treated with ADT and consider whether the incidence of such events differs with the treatment modality. We discuss possible mechanisms by which such events might be mediated, including the roles of testosterone and the GnRH receptor, and consider current guidelines in light of these data.
Commentaries:
• Big Data: Not Really the Same as Level 1 Data
• The Double-Edged Sword of ADT: Emerging Evidence of Cardiovascular, Pulmonary, and Renal Risks
• Big Data: Not Really the Same as Level 1 Data
• The Double-Edged Sword of ADT: Emerging Evidence of Cardiovascular, Pulmonary, and Renal Risks
Chemotherapy for Soft-Tissue Sarcomas
In patients with high-risk localized disease, the use of systemic chemotherapy should be strongly considered to delay recurrence and/or reduce the patient's risk of developing metastatic disease. In patients with metastatic disease, systemic chemotherapy remains the mainstay of treatment.
In patients with high-risk localized disease, the use of systemic chemotherapy should be strongly considered to delay recurrence and/or reduce the patient's risk of developing metastatic disease. In patients with metastatic disease, systemic chemotherapy remains the mainstay of treatment.
Commentaries:
• Chemotherapy in Soft-Tissue Sarcoma: Where Do We Go From Here?
• Cytotoxic Chemotherapy for Adult Soft-Tissue Sarcomas: A Lesson in Humility
• Chemotherapy in Soft-Tissue Sarcoma: Where Do We Go From Here?
• Cytotoxic Chemotherapy for Adult Soft-Tissue Sarcomas: A Lesson in Humility
Stopping Cancer Treatment: It Isn't Sophie's Choice
Multiple lines of therapy in stage IV tumors have diminishing benefit, and this is where patients and families need to know that the finish line is the same.
Multiple lines of therapy in stage IV tumors have diminishing benefit, and this is where patients and families need to know that the finish line is the same.
Vitamin D Levels Linked to Colorectal Cancer Survival
Newly diagnosed metastatic colorectal cancer patients with higher vitamin D levels had better outcomes after treatment with chemotherapy and a targeted agent.
Newly diagnosed metastatic colorectal cancer patients with higher vitamin D levels had better outcomes after treatment with chemotherapy and a targeted agent.
Intense Chemo Plus Avastin Ups Survival in Colon Cancer
Initial treatment with FOLFOXIRI plus bevacizumab in metastatic colorectal cancer patients improved survival over FOLFIRI and bevacizumab by more than 4 months.
Initial treatment with FOLFOXIRI plus bevacizumab in metastatic colorectal cancer patients improved survival over FOLFIRI and bevacizumab by more than 4 months.
Tambahkan Komentar